Financial health
- Operating income covered interest expense 76× in the latest year, up from -53.3× 4 years ago.
5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | $48M | — | — | -$80M | — | $220M |
| 2024 | — | -$1M | — | — | $80M | — | $270M |
| 2023 | — | -$22M | — | — | $22M | — | $279M |
| 2022 | — | -$358M | — | — | $119M | — | $247M |
| 2021 | — | -$128M | — | — | -$171M | — | $213M |
How the market has priced RERE against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
See the revenue and net-income charts above for Atrenew Inc.'s multi-year trend.
As of FY2025, Atrenew Inc. reported — of total debt against $220M of cash; operating income covered interest expense 76×.
In FY2025, gross margin was —, operating margin —, and net margin —.
As of Jun '26, Atrenew Inc. traded at a price-to-earnings ratio of about 12.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.